Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 478


Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.

Ontiveros F, Wilson EB, Livingstone AM.

Immunology. 2011 Apr;132(4):549-58. doi: 10.1111/j.1365-2567.2010.03400.x. Epub 2011 Jan 24.


NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.

Stober D, Jomantaite I, Schirmbeck R, Reimann J.

J Immunol. 2003 Mar 1;170(5):2540-8.


NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.

Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V.

J Immunol. 2003 Nov 15;171(10):5140-7.


Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.

Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS.

J Immunol. 2004 Apr 15;172(8):4762-9.


Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.

Ye Z, Ahmed KA, Hao S, Zhang X, Xie Y, Munegowda MA, Meng Q, Chibbar R, Xiang J.

Autoimmunity. 2008 Nov;41(7):501-11. doi: 10.1080/08916930802069256.


Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.

Wang JC, Livingstone AM.

J Immunol. 2003 Dec 15;171(12):6339-43.


H2-M3-restricted CD8+ T cells augment CD4+ T-cell responses by promoting DC maturation.

Chow MT, Teh HS.

Eur J Immunol. 2010 May;40(5):1408-17. doi: 10.1002/eji.200939934.


Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.

Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA.

Immunol Cell Biol. 2011 Nov;89(8):904-13. doi: 10.1038/icb.2011.13. Epub 2011 Mar 8.


Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.

Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM.

Clin Exp Immunol. 2011 Mar;163(3):381-91. doi: 10.1111/j.1365-2249.2010.04305.x. Epub 2011 Jan 14.


Supplemental Content

Support Center